Drugs News and Research

RSS

New series of filters screen compounds for drug development

The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute's medicinal chemistry group.

25 Mar 2010

Study: MetAP inhibitors prevent TB growth in test tubes

Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.

25 Mar 2010

Democrats expect to end debate early on health reconciliation bill

Senate Democratic leaders are trying to end the debate on a bill that "fixes" the health overhaul law that President Barack Obama signed Tuesday. Once the debate ends, the Senate is expected to begin voting on a number of Republican amendments, The New York Times reports.

24 Mar 2010

Patients and doctors' views on important endpoints in incurable metastatic breast cancer

Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.

24 Mar 2010

FHI, Duke University Medical Center pertner to improve TB treatment

Family Health International, a nonprofit global health and development organization working to improve the lives of the world's most vulnerable people, recently joined the Tuberculosis Trials Consortium, an international body that researches new TB drugs and treatment strategies. The consortium is funded by the US Centers for Disease Control and Prevention. As part of the consortium, FHI is partnering with Duke University Medical Center to conduct clinical trials that aim to reduce the duration of TB treatment and lessen the side effects of TB drugs.

24 Mar 2010

Vaccine deal signed - 47 developing countries to receive low priced vaccines by 2015

Pharmaceutical giants have signed a historical 10-year deal on Tuesday pledging the supply of 60 million doses a year of pneumococcal vaccines at cut-prices to developing nations.

24 Mar 2010

AHF to protest against Merck's pricing of Isentress

AIDS Healthcare Foundation will host a protest Wednesday morning, March 24th at 10:30am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, one of the most expensive first-line AIDS treatment in the US, during the Barclays Capital Global Healthcare Conference.

24 Mar 2010

MHPA commends Congress for improving state Medicaid programs

"Congress has made a historical commitment to providing access to health care for 16 million low-income Americans through expansion of the Medicaid program. The bills also maintain and strengthen health coverage for kids through the Children's Health Insurance Program."

24 Mar 2010

FDA recommends clinicians temporarily suspend use of Rotarix vaccine

The agency recently became aware that an independent U.S. academic research team, using a novel technique, has found DNA from porcine circovirus 1 (PCV1) in Rotarix, which is manufactured by GlaxoSmithKline. PCV1 is not known to cause illness in humans or other animals. In addition, Rotarix has been studied extensively, before and after approval, and found to have an excellent safety record.

24 Mar 2010

Analgesics can decrease risk of breast or ovarian cancer

Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer.

24 Mar 2010

Complete structure of Insulin receptor discovered - may assist in drug development for diabetes

Insulin is one of the most commonly used therapeutic agents used in diabetes. While the structure of this complex protein has been studied in detail there were parts of the receptor for insulin that were not clearly defined till now. This receptor is a protein that exists on the surfaces of cells and binds to the insulin molecule. These receptors are responsible for the action of insulin on the cells.

24 Mar 2010

Senate briefing on World TB Day

A Senate briefing, Bringing Established Methods to Scale: New Perspectives in the Changing World of TB, to discuss TB and drug-resistant TB, including multidrug-resistant TB and extensively-drug resistant, the impact on global health and the current state of surveillance, diagnosis and treatment around the world.

24 Mar 2010

Bioalliance Pharma's anti-emetic drug Setofilm receives European approval

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced approval for Setofilm® in 16 European countries.

24 Mar 2010

Obama and Congress deliver meaningful healthcare reform

Alliance President and CEO joins President Obama, Members of Congress, and leading health advocates at President's speech marking signing of health insurance reform into law

24 Mar 2010

Medicare steps up efforts to monitor seniors' prescriptions

Writing for Kaiser Health News in collaboration with USA Today, Susan Jaffe reports on how Medicare is expanding a program to make sure that some older adults use the right drugs and take them correctly to prevent harmful side effects or interactions.

24 Mar 2010

FDA grants Orphan Drug Designation for anti-diabetic drug

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

First Edition: March 23, 2010

Today's headlines cover a range of topics related to the newly passed health overhaul bill, from the surrounding opposition and next steps to some of its policy implications.

23 Mar 2010